triphenyltetrazolium has been researched along with cannabidiol in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, K; Egashira, N; Fujiwara, M; Hasebe, N; Hayakawa, K; Ikeda, T; Inui, K; Iwasaki, K; Mishima, K; Takamatsu, F; Yasuda, H | 1 |
| Abe, K; Egashira, N; Fujioka, M; Fujiwara, M; Hasebe, N; Hayakawa, K; Hazekawa, M; Irie, K; Iwasaki, K; Mishima, K; Nozako, M; Orito, K | 1 |
| Egashira, N; Fujioka, M; Fujiwara, M; Hayakawa, K; Hazekawa, M; Irie, K; Iwasaki, K; Katsurabayashi, S; Mishima, K; Mishima, S; Orito, K; Takasaki, K | 1 |
3 other study(ies) available for triphenyltetrazolium and cannabidiol
| Article | Year |
|---|---|
Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism.
Topics: Analysis of Variance; Animals; Body Temperature; Brain Infarction; Cannabidiol; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Fever; Infarction, Middle Cerebral Artery; Male; Mice; Neuroprotective Agents; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Tetrazolium Salts; Time Factors | 2004 |
Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism.
Topics: Animals; Behavior, Animal; Cannabidiol; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Functional Laterality; Glutamic Acid; Infarction, Middle Cerebral Artery; Male; Mice; Motor Activity; Neuroprotective Agents; Perfusion; Peroxidase; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Tetrazolium Salts; Time Factors | 2007 |
Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism.
Topics: Analysis of Variance; Animals; Blood Pressure; Brain Injuries; Calcium-Binding Proteins; Cannabidiol; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Gene Expression Regulation; Glial Fibrillary Acidic Protein; HMGB1 Protein; In Situ Nick-End Labeling; Infarction, Middle Cerebral Artery; Male; Mice; Microfilament Proteins; Motor Activity; Neurologic Examination; Peroxidase; Phosphopyruvate Hydratase; Reperfusion; Tetrazolium Salts; Time Factors | 2008 |